Whither Doha, IP and health

Thanks to the IP Watch for comprehensive commentary on developments and review in respect of Doha, IP and accessing medicines. Not entirely surprisingly, there seems to be a range of views....although most interesting is the reference to a critical Oxfam report.

Against this same backdrop was discussion in the EC about research (and its funding) into neglected diseases. Focus on this (http://www.ip-watch.org/weblog/index.php?p=451&res=800&print=0) has noted the absence of IP from the debate and has seen this as largely positive, as it was taking place outside the market framework. I am rather sceptical about this - whatever one thinks about IP, it exists. It is not sensible to ignore it - other regimes and principles, such as competition and human rights, must either work within or around IP or prevail over it.